Stoke Therapeutics, Inc. Net Fee Amt
Stoke Therapeutics, Inc. (STOK) had Net Fee Amt of $8.06 thousand as of 2026-07-31, per its S-8 filed 2026-08-03.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-03
- 2026-07-31: Net Fee Amt $8.06K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-31 | $8.06K S-8 · filed 2026-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |